AR112121A1 - PHARMACEUTICAL COMBINATION PRODUCT INCLUDING BOTULINUM TOXIN FOR THE TREATMENT OF ERECTILE DYSFUNCTION - Google Patents

PHARMACEUTICAL COMBINATION PRODUCT INCLUDING BOTULINUM TOXIN FOR THE TREATMENT OF ERECTILE DYSFUNCTION

Info

Publication number
AR112121A1
AR112121A1 ARP180101493A ARP180101493A AR112121A1 AR 112121 A1 AR112121 A1 AR 112121A1 AR P180101493 A ARP180101493 A AR P180101493A AR P180101493 A ARP180101493 A AR P180101493A AR 112121 A1 AR112121 A1 AR 112121A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
combination product
treatment
botulinum toxin
erectile dysfunction
Prior art date
Application number
ARP180101493A
Other languages
Spanish (es)
Inventor
Pierre Denys
Franois Giuliano
Original Assignee
Univ De Versailles St Quentin En Yvelines
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Versailles St Quentin En Yvelines, Hopitaux Paris Assist Publique filed Critical Univ De Versailles St Quentin En Yvelines
Publication of AR112121A1 publication Critical patent/AR112121A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto de combinación farmacéutico que comprende toxina botulínica y al menos un agente proeréctil para uso simultáneo, secuencial o separado en el tratamiento de disfunción eréctil. Reivindicación 10: Producto de combinación farmacéutico de acuerdo a la reivindicación 9, en donde el inhibidor de PDE5 es seleccionado de avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, o una sal farmacéuticamente aceptable de los mismos. Reivindicación 11: Producto de combinación farmacéutico de acuerdo a la reivindicación 10, en donde el inhibidor de PDE5 es citrato de sildenafil.A pharmaceutical combination product comprising botulinum toxin and at least one pro-ectile agent for simultaneous, sequential or separate use in the treatment of erectile dysfunction. Claim 10: Pharmaceutical combination product according to claim 9, wherein the PDE5 inhibitor is selected from avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, or a pharmaceutically acceptable salt thereof. Claim 11: Pharmaceutical combination product according to claim 10, wherein the PDE5 inhibitor is sildenafil citrate.

ARP180101493A 2017-06-02 2018-06-04 PHARMACEUTICAL COMBINATION PRODUCT INCLUDING BOTULINUM TOXIN FOR THE TREATMENT OF ERECTILE DYSFUNCTION AR112121A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305653 2017-06-02

Publications (1)

Publication Number Publication Date
AR112121A1 true AR112121A1 (en) 2019-09-25

Family

ID=59276633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101493A AR112121A1 (en) 2017-06-02 2018-06-04 PHARMACEUTICAL COMBINATION PRODUCT INCLUDING BOTULINUM TOXIN FOR THE TREATMENT OF ERECTILE DYSFUNCTION

Country Status (1)

Country Link
AR (1) AR112121A1 (en)

Similar Documents

Publication Publication Date Title
CL2020000122A1 (en) Treatment methods for cystic fibrosis.
ECSP066990A (en) FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE PRINCIPLE CONTAINING VARDENAFILO
NI201800102A (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PYRROLIDIN-1-IL) -PYRAZOLE [1,5-A] PYRIMIDIN-3-IL) -3 -HYDROXIPYRROLIDINE-1-CARBOXAMIDE.
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
AR084691A1 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
AR102973A1 (en) USE OF THE 3,5-DIHIDROXI-4-ISOPROPIL-TRANS-ESTILBENE COMPOUND FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, SUCH COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
CO2021000174A2 (en) Topical compositions for pain relief
DOP2022000053A (en) BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE
CL2011000710A1 (en) Pharmaceutical combination comprising a specific smoothened inhibitor and a specific pi3 kinase inhibitor; and use in the treatment of cancer.
CO2020013600A2 (en) Treatment of hidradenitis suppurativa using jak inhibitors
PA8669801A1 (en) ASSOCIATION BETWEEN RAILWAY AND AN ARTEMISININE DERIVATIVE FOR TREATMENT OF PALUDISM
NI202100047A (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF alpha1-ANTITRYPSIN DEFICIENCY
AR101414A1 (en) PIRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS
AR112144A1 (en) COMPOUNDS FOR THE TREATMENT OF SARCOMA
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
CL2007002878A1 (en) PHARMACEUTICAL AGENT UNDERSTANDING 1) AN HER2 INHIBITOR THAT HAS A PIRROLOPIRIMIDINE OR PIRAZOLOPIRIMIDINE SKELETON AND 2) A HORMONAL OR ANTI-BANK THERAPEUTIC AGENT IN COMBINATION; AND USE FOR THE PREVENTION OR TREATMENT OF CANCER.
AR112121A1 (en) PHARMACEUTICAL COMBINATION PRODUCT INCLUDING BOTULINUM TOXIN FOR THE TREATMENT OF ERECTILE DYSFUNCTION
AR047880A1 (en) COMBINATION OF A RENIN AND DIURETIC INHIBITOR
UY37412A (en) INDAZOL COMPOUNDS FOR USE IN INJURY OF TENDONS AND / OR LIGAMENTS
CO2019007671A2 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease
HN2010001775A (en) ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A SALT OF KETEROLACO AND VITAMINS OF COMPLEX B
CL2018000220A1 (en) Innovative dual oral delayed release composition of dexlansoprazole
AR103484A1 (en) TRIPTOLID AND ITS DERIVATIVES IN THE TREATMENT OF PRECANCER TUMORS AND SKIN PATHOLOGIES
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
MX2022006180A (en) Macrocyclic sulfonyl derivatives as mcl-1 inhibitors.

Legal Events

Date Code Title Description
FB Suspension of granting procedure